RESEARCH ARTICLE

Antipsychotic Dose Mediates the Association between Polypharmacy and Corrected QT Interval

Corrado Barbui1*, Irene Bighelli1, Giuseppe Carrà2, Mariasole Castellazzi1, Claudio Lucii3, Giovanni Martinotti4, Michela Nosè1, Giovanni Ostuzzi1, STAR NETWORK INVESTIGATORS¶

1 WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Section of Psychiatry, University of Verona, Verona, Italy, 2 Division of Psychiatry, University College of London, UK, and Department of Medicine and Surgery, University of Milano Bicocca, Milan, Italy, 3 Department of Mental Health, Siena, Italy, 4 Department of Neuroscience, Imaging and Clinical Sciences, University of Chieti, Chieti, Italy

¶ Membership of the STAR NETWORK INVESTIGATORS is provided in the Acknowledgments
* corrado.barbui@univr.it

Abstract

Antipsychotic (AP) drugs have the potential to cause prolongation of the QT interval corrected for heart rate (QTc). As this risk is dose-dependent, it may be associated with the number of AP drugs concurrently prescribed, which is known to be associated with increased cumulative equivalent AP dosage. This study analysed whether AP dose mediates the relationship between polypharmacy and QTc interval. We used data from a cross-sectional survey that investigated the prevalence of QTc lengthening among people with psychiatric illnesses in Italy. AP polypharmacy was tested for evidence of association with AP dose and QTc interval using the Baron and Kenny mediational model. A total of 725 patients were included in this analysis. Of these, 186 (26%) were treated with two or more AP drugs (AP polypharmacy). The mean cumulative AP dose was significantly higher in those receiving AP polypharmacy (prescribed daily dose/defined daily dose = 2.93, standard deviation 1.31) than monotherapy (prescribed daily dose/defined daily dose = 0.82, standard deviation 0.77) (z = −12.62, p < 0.001). Similarly, the mean QTc interval was significantly longer in those receiving AP polypharmacy (mean = 420.86 milliseconds, standard deviation 27.16) than monotherapy (mean = 413.42 milliseconds, standard deviation 31.54) (z = −2.70, p = 0.006). The Baron and Kenny mediational analysis showed that, after adjustment for confounding variables, AP dose mediates the association between polypharmacy and QTc interval. The present study found that AP polypharmacy is associated with QTc interval, and this effect is mediated by AP dose. Given the high prevalence of AP polypharmacy in real-world clinical practice, clinicians should consider not only the myriad risk factors for QTc prolongation in their patients, but also that adding a second AP drug may further increase risk as compared with monotherapy.
Introduction

Antipsychotic (AP) drugs as a group have long been known to have the potential to cause prolongation of the QT interval corrected for heart rate (QTc) [1;2]. Data on individual AP drugs are more controversial, with individual phenothiazines and butyrophenones (e.g., haloperidol) carrying a higher risk as compared with some individual second-generation AP drugs, such as quetiapine and olanzapine, which may have a moderate risk, or aripiprazole, possibly showing a lower potential to cause QTc prolongation [3;4]. However, as many other risk factors for QTc prolongation have been identified [2;5], these data remain difficult to interpret and somehow controversial [6].

As the risk is considered dose-dependent [3;7;8], it may also be associated with the number of AP drugs concurrently prescribed, as AP polypharmacy has consistently been shown to be associated with increased combined equivalent AP dosage [9;10]. However, a recent systematic review of 10 clinical trials, 4 observational studies, and 7 case reports, failed to find that AP polypharmacy worsens QTc interval, although it pointed out that the evidence is scarce and inconsistent [11]. In a cross-sectional survey carried out to estimate the prevalence of QTc lengthening in a sample of people with psychiatric illnesses, we showed that AP polypharmacy was positively associated with QTc prolongation, but the sample of included patients was quite heterogeneous in terms of cardiovascular disorders and use of medications [4]. Besides, whether AP dose mediates the association between polypharmacy and QTc interval has not been investigated yet, largely remaining unknown.

The present study analysed the mediational role of AP dose in the relationship between polypharmacy and QTc interval. We additionally investigated whether haloperidol and individual second-generation AP drugs are associated with QTc prolongation, taking into account AP polypharmacy and dose.

Materials and Methods

Study Participants

This study is based on data from a cross-sectional survey that investigated the prevalence of QTc lengthening among people with psychiatric illnesses in Italy [4]. The study was carried out in 35 Italian psychiatric services that are part of the STAR (Servizi Territoriali Associati per la Ricerca) Network, a research group established to produce scientific knowledge by collecting data under ordinary clinical practice. The study design has already been presented elsewhere [4]. Briefly, during a three-month recruitment period, a consecutive unselected series of both in- and out- patients were invited to participate. Inpatients aged 18 or above were included if they gave informed written consent, performed an ECG during hospital stay, and were receiving pharmacological treatment with psychotropic drugs on the day of ECG recording. For inpatients with more than one ECG during hospital stay, the first was considered. Outpatients aged 18 or above were included if they gave informed written consent, underwent ECG examination during the recruitment period, and were receiving pharmacological treatment with psychotropic drugs on the day of ECG performance. For outpatients with more than one ECG during the recruitment period, we considered the earliest. A specific psychiatric diagnosis was not a requirement for inclusion in the study. The study received ethical approval by the Ethics Committee of the Azienda Ospedaliera Universitaria Integrata, Verona (Approval Number 2409) and by the Ethics Committee of each participating site, and all participants gave their informed written consent. As all participants had full mental capacity, no specific measure was adopted to determine capacity to consent.
Data Collection
Socio-demographic and clinical characteristics were collected from medical records, including ICD-10 psychiatric diagnosis, alcohol/substances use, recruitment setting, being admitted for drug overdose, electrolyte (sodium, potassium, calcium, chloride) imbalances, cardiovascular disorders, drug treatments for psychiatric disorders, drug treatments for other disorders and antipsychotic prescribed daily doses. Drugs were classified following the Anatomical Therapeutic Chemical Classification (ATC) system and, following the Arizona Cert (AzCERT), those that can cause QTc lengthening under normal clinical usage were identified.

Antipsychotic drug doses (N05A of the ATC group excluding N05AN, lithium) were converted into multiples of the Defined Daily Dose (DDD) for each drug by dividing the prescribed daily dose (PDD) by the DDD [PDD/DDD] [12]. The DDD is the international unit of drug utilisation approved by the World Health Organisation for drug use studies. It is a theoretical unit of measurement defined as the assumed average maintenance daily dose for a drug, used for its main indication in adults. Expression of drug use in terms of multiples of DDDs allows calculating, for each patient, a cumulative measure of drug consumption taking into account the concurrent use of more than one agent. A PDD/DDD ratio of one indicates that the dose prescribed is equal to the DDD of that drug; a ratio greater than one indicates a dosage higher than the DDD of that drug, while a ratio lower than one means a dose lower than the DDD of that drug [13].

The QTc interval estimation was obtained in each participating site from standard 12-lead ECG. The most common way for interpreting the QT interval is to divide its value by the square root of the RR interval expressed in seconds, namely, by using Bazett’s formula for correction. The QTc was determined by examining lead II with automatic data acquisition and was confirmed by a cardiologist who was blind to the patient’s clinical condition.

Sample Definition
For the purposes of this analysis, from the entire sample of recruited patients we excluded those with risk factors for QTc lengthening (Fig 1). Out of 1776 consecutive patients treated with AP drugs, we excluded 1051 patients for the following reasons: cardiovascular disorders and/or cardiovascular drug treatments; electrolyte imbalances when the ECG was performed; alcohol and/or substance use disorders; drug overdose as reason for admission; use of any other medicines associated with QTc lengthening according to AzCERT (Fig 1).

Data Analysis
We first tested AP polypharmacy (use of two or more AP drugs) as a dichotomous variable for evidence of association with socio-demographic information, clinical data and drug use. Chi-squared statistics were calculated for pairs of dichotomous variables, and Mann-Whitney statistics were used to analyse continuous variables by AP polypharmacy.

Subsequently, AP polypharmacy was tested for evidence of association with AP dose and QTc interval in univariate nonparametric test for trend across ordered groups, which is an extension of the Wilcoxon rank-sum test [14]. As additional step, the Baron and Kenny mediational model was applied [15;16]. According to this approach, a mediating role of a variable exists when four conditions are met: (i) the predictor variable (AP polypharmacy) must be significantly related to the outcome variable (QTc interval); (ii) the hypothesized mediator (AP dose) must be significantly related to the predictor variable (AP polypharmacy); (iii) the mediator (AP dose) must be significantly related to the outcome (QTc interval); and (iv) the relationship between the predictor (AP polypharmacy) and the outcome (QTc interval) must be attenuated when controlling for the mediator (AP dose). If the predictor remains significant
1776 consecutive patients treated with antipsychotics

- 669 patients excluded because of cardiovascular disorders (498) and/or cardiovascular drug treatments (304)
- 106 patients excluded because of electrolyte imbalances (25 sodium, 34 potassium, 41 chloride, 28 calcium)
- 208 patients excluded because of alcohol and/or substance use disorders
- 35 patients excluded because of recent drug overdose
- 33 additional patients excluded because treated with other medicines associated with QTc lengthening according to AzCERT

725 patients treated with antipsychotics and no cardiovascular disorders or other risk factors for QTc lengthening

- 539 patients treated with one antipsychotic (monotherapy)
- 186 patients treated with two or more antipsychotics (polypharmacy)

Fig 1. Flow chart of inclusion and exclusion criteria of cohort of patients treated with antipsychotic drugs.

doi:10.1371/journal.pone.0148212.g001
when the mediator is controlled for, mediation is deemed to be partial. When controlling for the mediator renders the predictor non-significant, mediation is deemed complete [15;16]. The four conditions of the Baron and Kenny mediational model were tested by means of four linear regression analyses, adjusting for the following confounding variables: sex (female = 1, male = 0), age (years, continuous variable), psychosis or related disorder (no = 0, yes = 1), length of illness (years, continuous variable), inpatient status (no = 0, yes = 1), treatment with AD drugs (no = 0, yes = 1), treatment with mood stabilisers (no = 0, yes = 1). A nonparametric bootstrap method of statistical accuracy was used, assuming that the observed distribution of the present sample was a good estimate of the true population distribution [17].

In addition, we tested whether use of haloperidol, risperidone, olanzapine, clozapine, quetiapine, paliperidone or aripiprazole was associated with QTc interval. For each of these drugs, nonparametric bootstrap linear regression analyses were conducted including (i) the confounding variables reported above (first analysis), (ii) the confounding variables reported above plus AP polypharmacy (second analysis), and (iii) the confounding variables reported above plus AP polypharmacy and AP dose (third analysis). Statistical analysis was carried out with STATA 13.

Results

Patient Characteristics

A total of 725 patients were included in this analysis (Fig 1). The mean QTc interval was 412.40 ms in men (SD 28.35) and 417.70 ms (SD 32.20) in women. In men, 30 patients (9.23%) showed a QTc longer than 450 ms, while in women 12 patients (3%) showed a QTc longer than 470 ms. Of the whole sample, 186 (26%) were treated with two or more AP drugs (AP polypharmacy). The main socio-demographic and clinical characteristics are presented in Table 1. Patients receiving AP polypharmacy were more often men, with psychotic disorders, and slightly younger than patients treated with one AP only. In terms of drug treatments, use of haloperidol, clozapine, quetiapine and aripiprazole was more frequent in patients treated with AP polypharmacy (Table 1). AD drugs were more often used in those receiving one AP only.

AP Polypharmacy, AP Dose and QTc Interval

The mean AP dose was significantly higher in those receiving AP polypharmacy (PDD/DDD = 2.93, SD 1.31) than in those receiving AP monotherapy (PDD/DDD = 0.82, SD 0.77) ($z = -12.62, p < 0.001$). Similarly, the mean QTc interval was significantly longer in those receiving AP polypharmacy (mean = 420.86 ms, SD 27.16) than in those receiving AP monotherapy (mean = 413.42 ms, SD 31.54) ($z = -2.70, p = 0.006$). Fig 2 shows that the number of AP drugs received was significantly associated with AP dose ($z$ test for trend = 12.35, $p < 0.001$) and QTc interval ($z$ test for trend = 3.35, $p = 0.001$).

Fig 3 presents the results of the Baron and Kenny approach. It shows that, after adjustment for confounding variables, AP polypharmacy was significantly associated with QTc interval (Model 1); AP polypharmacy was significantly associated with AP dose (Model 2); AP dose was significantly associated with QTc interval (Model 3); after controlling for AP dose, AP polypharmacy was no longer associated with QTc interval (Model 4). This suggests that AP dose mediates the association between polypharmacy and QTc interval.

Individual AP Drug and QTc Interval

We tested whether haloperidol and individual second-generation AP drugs were associated with QTc lengthening (Table 2), controlling for AP polypharmacy and dose. We failed to find
an association between individual AP drugs and QTc interval, but we observed that people on aripiprazole were significantly less likely to show QTc prolongation, which persisted after controlling for AP dose and polypharmacy (Table 2).

Discussion

The present study found that AP polypharmacy is associated with QTc interval, and this effect is mediated by AP dose. This finding is noteworthy as clinicians may not be fully aware that AP polypharmacy is associated with high doses, erroneously arguing that AP polypharmacy reduces the total amount of AP medication [18]. The risk of QTc lengthening might therefore be underestimated in patients exposed to two or more concurrent AP drugs.
Fig 2. Distribution of antipsychotic dose and QTc interval by number of antipsychotics.

doi:10.1371/journal.pone.0148212.g002
Risk associated with haloperidol and individual second-generation AP drugs provided additional clinically interesting insights. First, we failed to detect an increased risk associated with haloperidol. We argue that this does not suggest a safe profile of haloperidol but, rather, compliance with current safety warnings [19], which may have led to the selection of individuals without ECG abnormalities. Second, aripiprazole resulted, in comparison with all other AP drugs, associated with a reduced risk of QTc prolongation. This finding is consistent with the conclusions of a systematic review that investigated the cardiac safety of aripiprazole treatment in patients at high risk for torsade [20]. Based on more than 100 preclinical, clinical, and epidemiological studies, the review found strong evidence in QTc data supporting a safe cardiac profile [20]. In addition, experimental data from placebo and head-to-head comparisons between...

![Fig 3. Mediation model showing both the direct and the mediated pathways of the relationship between antipsychotic polypharmacy and QTc interval. Observed coefficients (β) with standard errors (SE) and p-values are reported. doi:10.1371/journal.pone.0148212.g003](image)

Table 2. Relationship between exposure to haloperidol and individual second-generation AP drugs and QTc interval.

| Drug              | Coefficient (bias corrected 95% CI) | z value | P value | Coefficient (bias corrected 95% CI) | z value | P value | Coefficient (bias corrected 95% CI) | z value | P value |
|-------------------|------------------------------------|---------|---------|------------------------------------|---------|---------|------------------------------------|---------|---------|
| Haloperidol       | 3.64 (-2.85 to 10.13)              | 1.10    | 0.272   | 2.27 (-2.57 to 7.12)              | 0.92    | 0.358   | 2.82 (-2.10 to 7.76)              | 1.12    | 0.261   |
| Risperidone       | -2.87 (-10.84 to 5.09)             | -0.71   | 0.479   | -2.79 (-9.79 to 4.20)             | -0.78   | 0.434   | -2.08 (-9.74 to 5.57)             | -0.78   | 0.434   |
| Olanzapine        | -0.84 (-5.00 to 3.31)              | -0.40   | 0.690   | -1.05 (-6.01 to 3.90)             | -0.42   | 0.676   | -1.86 (-7.15 to 3.42)             | -0.53   | 0.593   |
| Clozapine         | -0.04 (-8.66 to 8.56)              | -0.01   | 0.991   | -0.88 (-11.50 to 9.74)            | -0.16   | 0.871   | -0.82 (-10.02 to 8.36)            | -0.18   | 0.860   |
| Quetiapine        | 4.57 (-1.51 to 10.66)              | 1.47    | 0.141   | 3.69 (-2.20 to 9.60)              | 1.23    | 0.222   | 3.92 (-2.34 to 10.20)             | 1.23    | 0.220   |
| Paliperidone      | -2.38 (-11.42 to 6.66)             | -0.52   | 0.606   | -2.47 (-11.91 to 6.97)            | -0.51   | 0.608   | 0.46 (-8.95 to 8.03)              | -0.11   | 0.915   |
| Aripiprazole      | -10.83 (-19.06 to -2.61)           | -2.58   | 0.010   | -11.43 (-19.07 to -3.80)          | -2.94   | 0.003   | -14.00 (-25.10 to -2.91)          | -2.47   | 0.013   |

CI = Confidence interval; AD = antidepressants; MS = mood stabilisers
doi:10.1371/journal.pone.0148212.t002
different AP drugs found that aripiprazole was not associated with significant QTc prolongation compared with placebo, and that it was the second best choice in terms of risk of ECG abnormalities second only to lurasidone [21].

These findings should be interpreted bearing in mind some study limitations. A first concern refers to the possibility of confounding, as there are several risk factors for QTc prolongation [2;5]. In this analysis, instead of statistically controlling for some of these risk factors, we restricted the analysis to patients without some characteristics that are known to be associated with QTc lengthening, including cardiovascular disorders and a number of medications. Although this has indubitably increased homogeneity of the study sample, we acknowledge that we were not able to take into consideration other potential contributing factors, such as obesity, malnutrition or hepatic dysfunctions. For example, recent data have shown that AP drugs may be associated with non-alcoholic fatty liver disease (NAFLD) [22], and NAFLD has been shown to increase the risk of a wide spectrum of cardiovascular and cardiac abnormalities, including increased QTc interval [23]. Therefore, AP drugs, in addition to direct cardiac toxicity, may be conducive to increased QTc interval via dysmetabolism and NAFLD. Another limitation relates to the small numbers of patients taking some individual drugs, resulting in both limited statistical power to detect associations with QTc interval and unfeasibility to test associations between QTc prolongation and some “classical” AP combinations (e.g. those involving aripiprazole or clozapine) recommended by evidence-based guidelines [24]. Last, the choice of using ECG data collected for clinical purposes, which may have introduced some heterogeneity in terms of different centres measuring the QT interval in slightly different ways, was motivated by an attempt to resemble as much as possible clinical practice.

Given the high prevalence of AP polypharmacy in real-world clinical practice, still in absence of solid evidence, this study has several implications for routine treatment programmes. Clinicians should bear in mind that since AP polypharmacy is not associated with reduced cumulative dose of AP drugs [25], but the combined equivalent is significantly higher in those receiving AP polypharmacy compared with those on monotherapy, this may actually worsen the QTc interval. Guidelines for the use of AP polypharmacy are progressively moving from recommending it only in patients with clozapine-refractory psychosis [26] towards a more extensive use [27]. Thus, clinicians should consider not only the myriad risk factors for QTc prolongation in their patients, but also that adding a second AP drug may further increase risk as compared with monotherapy. In patients exposed to AP polypharmacy, it may be prudent to monitor QTc before treatment, and then regularly during treatment, depending on the estimated risk.

Clinicians should also consider that AP polypharmacy is not unalterable. Switching from polypharmacy to monotherapy has been shown to be feasible in a majority of patients with schizophrenia, and assertive educational interventions, rather than educational approaches alone, were found to be effective supportive strategies in reducing AP polypharmacy [28].

In terms of implications for research, these data suggest that controlled, high-quality AP combination trials are necessary to determine the effectiveness, safety, and role of AP polypharmacy in the management of severely ill patients. Among safety outcomes, studies should always include measures of cardiac functioning, including the QTc interval.

**Acknowledgments**

The STAR NETWORK Investigators are: T. Acciavatti (Chieti), A. Adamo (Palermo), A. Aguglia (Torino), C. Albanese (Siena), S. Baccaglini (Verona), F. Bardicchia (Grosseto), R. Barone (Garbagnate Milanese), Y. Barone (Roma), F. Bartoli (Milano), C. Bergamini (Verona), F. Bertolini (Verona), I. Bighelli (Verona), S. Bolognesi (Siena), A. Bordone (Catania), P. Bortoloso
Author Contributions
Conceived and designed the experiments: CB IB GC MC CL GM MN GO. Analyzed the data: CB IB MC MN GO. Wrote the paper: CB IB GC MC CL GM MN GO.

References
1. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002; 62: 1649–71. PMID: 12109926
2. Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 2013; 54: 1–13. doi: 10.1016/j.psym.2012.11.001 PMID: 23295003
3. Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs 2014; 28: 887–920. doi: 10.1007/s40263-014-0196-9 PMID: 25168784
4. Nose M, Bighelli I, Castellazzi M, Martinotti G, Carra G, Lucii C, et al. Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study. Epidemiol Psychiatr Sci 2016; in press.
5. Rabkin SW. Impact of Age and Sex on QT Prolongation in Patients Receiving Psychotropics. Can J Psychiatry 2015; 60: 206–14. PMID: 26174524
6. Howland RH. QTc prolongation and haloperidol: just how risky is this drug? Psychosomatics 2014; 55: 741–2. doi: 10.1016/j.psym.2014.07.004 PMID: 25497511
7. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048–52. PMID: 10744090
8. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Tor sade de Pointes. Dtsch Arztebl Int 2011; 108: 687–93. doi: 10.3238/arztebl.2011.0667 PMID: 22114630
9. Biancosino B, Barbui C, Marmai L, Dona S, Grassi L. Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol 2005; 20: 305–9. PMID: 16192838
10. Barbui C, Nose M, Mazzi MA, Thornicroft G, Schene A, Becker T, et al. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol 2006; 21: 355–62. PMID: 17012982

11. Takeuchi H, Suzuki T, Remington G, Uchida H. Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review. Can J Psychiatry 2015; 60: 215–22. PMID: 26174525

12. Nose M, Barbui C. A simple approach to manage dosages in drug-epidemiology research. Epidemiol Psichiatr Soc 2008; 17: 186–7. PMID: 18924556

13. Nose M, Tansella M, Thornicroft G, Schene A, Becker T, Veronese A, et al. Is the Defined Daily Dose system a reliable tool for standardizing antipsychotic dosages? Int Clin Psychopharmacol 2008; 23: 287–90. doi: 10.1097/YIC.0b013e328303ac75 PMID: 18703938

14. Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985; 4: 87–90. PMID: 3992076

15. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986; 51: 1173–82. PMID: 3806354

16. Kraemer HC, Wilson GT, Fairburn CG, Agras WS. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 2002; 59: 877–83. PMID: 12365874

17. Efron B, Tibshirani R. Bootstrap methods of standard errors, confidence intervals, and other measures of statistical accuracy. Stat Science 1986; 1: 54–77.

18. Sernyak MJ, Rosenheck R. Clinicians’ reasons for antipsychotic coprescribing. J Clin Psychiatry 2004; 65: 1597–600. PMID: 15641863

19. Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med 2010; 5: E8–16.

20. Polcwiartek C, Sneider B, Graff C, Taylor D, Meyer J, Kanters JK, et al. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. Psychopharmacology (Berlin) 2015; 232: 3297–308.

21. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951–62. doi: 10.1016/S0140-6736(13)60733-3 PMID: 23810019

22. McNamara RK, Jandacek R, Rider T, Tso P, Cole-Strauss A, Lipton JW. Atypical antipsychotic medications increase postprandial triglyceride and glucose levels in male rats: relationship with stearoyl-CoA desaturase activity. Schizophr Res 2011; 129: 66–73. doi: 10.1016/j.schres.2011.03.016 PMID: 21474290

23. Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Pichiri I, et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 2014; 24: 663–9. doi: 10.1016/j.numecd.2014.01.005 PMID: 24594085

24. Kuipers E, Yesufu-Udechuku A, Taylor C, Kendall T. Management of psychosis and schizophrenia in adults: summary of updated NICE guidance. BMJ 2014; 348: g1173. doi: 10.1136/bmj.g1173 PMID: 24523363

25. John AP, Dragovic M. Antipsychotic polypharmacy is not associated with reduced dose of individual antipsychotics in schizophrenia. J Clin Psychopharmacol 2015; 35: 193–5. doi: 10.1097/JCP.0000000000000286 PMID: 25679123

26. Lochmann van Bennekom MW, Gjitsman HJ, Zitman FG. Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness. J Psychopharmacol 2013; 27: 327–36. doi: 10.1177/0269881113477709 PMID: 23413275

27. Stahl SM. Emerging guidelines for the use of antipsychotic polypharmacy. Rev Psiquiatr Salud Ment 2013; 6: 97–100. doi: 10.1016/j.rpsm.2013.01.001 PMID: 23485567

28. Tani H, Uchida H, Suzuki T, Fuji Y, Mimura M. Interventions to reduce antipsychotic polypharmacy: a systematic review. Schizophr Res 2013; 143: 215–20. doi: 10.1016/j.schres.2012.10.015 PMID: 23158205